Effect of Dexmedetomidine on Postoperative Delirium in Patients Undergoing Awake Craniotomies: a Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Postoperative delirium (POD) is a common complication, and the incidence of POD ranges from 10% to 60%. Previous studies suggested that frontal approach and tumor located at the temporal lobe were independent risk factors for POD after supratentorial tumor resections. Therefore, patients undergoing awake craniotomies are high-risk populations for POD. A lot of trials show that dexmedetomidine might help to reduce the incidence of delirium in patients undergoing non-cardiac surgery. However, the impact of dexmedetomidine (DEX) on POD for patients undergoing awake craniotomies remains unclear. The purpose of this study was to investigate the effect of DEX on POD in patients undergoing awake craniotomies.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients undergoing selective awake craniotomies.

• Age ≥18 years.

• Obtain written informed consent.

Locations
Other Locations
China
Beijing Tian Tan Hospital, Capital Medical University
RECRUITING
Beijing
Contact Information
Primary
Yuming Peng, MD,Ph.D
florapym766@163.com
8610-59976658
Time Frame
Start Date: 2022-03-31
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 210
Treatments
Active_comparator: DEX group
The DEX group patients will be received dexmedetomidine intraoperatively.
Placebo_comparator: Placebo group
The placebo group patients will be received 0.9% saline intraoperatively.
Related Therapeutic Areas
Sponsors
Leads: Beijing Tiantan Hospital

This content was sourced from clinicaltrials.gov